Earnings Call Summary | Haemonetics(HAE.US) Q1 2025 Earnings Conference
Earnings Call Summary | Haemonetics(HAE.US) Q1 2025 Earnings Conference
The following is a summary of the Haemonetics Corporation (HAE) Q1 2025 Earnings Call Transcript:
以下是美國血液技術(HAE)2025財年第一季度業績會交流會議記錄摘要:
Financial Performance:
金融業績:
Haemonetics reported Q1 revenue of $336 million, an 8% growth on a reported basis and 3% organically.
Adjusted earnings per diluted share declined by 3% to $1.02.
Adjusted gross margin was 55.3%, increasing by 110 basis points.
Adjusted operating income was $71 million, up by $0.8 million.
Forecasted adjusted earnings per share for FY 2025 range from $4.45 to $4.75.
美國血液技術第一季度營業收入爲33600萬美元,較報告基礎上增長8%,有機增長3%。
每股攤薄調整後盈利下降3%至1.02美元。
調整後毛利率爲55.3%,提高了110個點子。
調整後營業收入爲7100萬美元,增加了80萬美元。
2025財年調整後每股盈利預測爲4.45至4.75美元。
Business Progress:
業務進展:
Launched new products and integrated recent acquisitions.
Achieved 31% reported revenue growth in the Hospital business unit.
Plan to upgrade all Nexus customers in North America to Express Plus and Persona technologies before end of FY 2025.
Launching full market release of VASCADE MVP XL and planning to enter additional European markets this year.
Expecting strong year ahead with sustained revenue growth and enhanced productivity.
推出了新產品並整合了最近的收購。
醫院業務板塊的營業收入實現了31%的報告基礎增長。
計劃在2025財年結束前將北美的所有Nexus客戶升級至Express Plus和Persona技術。
推出VASCADE MVP XL並計劃進入其他歐洲市場,全面發佈市場。
預計未來一年將實現持續的營業收入增長和提高生產率。
Opportunities:
機會:
Continued demand for plasma and IG replacement therapies supporting long-term growth in plasma collections market.
New product launches like VASCADE MVP XL facilitating expansion in interventional procedures such as pulsed field ablation and left atrial appendage closures.
對血漿和免疫球蛋白(IG)替代療法的持續需求支持血漿採集市場的長期增長。
像VASCADE MVP XL這樣的新產品促進了介入性手術的擴張,例如脈衝場消融和左心耳封堵。
Risks:
風險:
Plasma revenue decline of 3%, influenced by customer transitions and unforeseen temporary customer plasma center outages.
Blood Center revenue decreased by 2% due to order timing among distributors and rationalizing the franchise to optimize contribution.
血漿收入下降3%,受客戶過渡和未預料的臨時客戶血漿中心停機影響。
血液中心的營收由於分銷商的訂單時間和優化特許經營權而下降了2%。
More details: Haemonetics IR
更多細節請查看美國血液技術的IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示:本文由AI生成。文章內容的準確性無法完全保證。有關更全面的詳細信息,請參閱IR網站。本文只是爲投資者提供參考,沒有任何指導或推薦建議。